Unlocking the immune checkpoint against a stealthy virus
A new study in *The Journal of Immunology* reveals how specific natural killer (NK) cells target B cells latently infected with Epstein-Barr virus (EBV). Using mass cytometry and functional assays, researchers identified a distinct NK cell population characterized by the expression of NKG2A alongside the activating receptors NKp30 and NKG2D. This population was shown to be crucial for the cytotoxicity of EBV-infected cells. The research further demonstrated that blocking the interaction between the inhibitory receptor NKG2A and its ligand HLA-E, or using HLA-E knockout cell lines, significantly enhanced NK cell-mediated killing. These findings pinpoint the NKG2A:HLA-E axis as a critical immune checkpoint in the control of latent EBV infection and a promising therapeutic target for EBV-associated malignancies.
Study Significance: This research directly connects functional genomics and immunogenetics to a concrete therapeutic strategy for viral oncology. For geneticists and clinicians focused on cancer genetics and gene therapy, it highlights how detailed mutational profiling of immune cell receptors can identify precise drug targets. The work suggests that pharmacogenomics approaches aimed at disrupting the NKG2A checkpoint could be integrated with existing cell therapies, like CAR-T, to improve outcomes for patients with EBV-driven lymphoproliferative diseases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
